Energy Failure, Glutamate and Neuropathology: Relevance to Neurodegenerative Disorders

  • Lechoslaw Turski
  • Chrysanthy Ikonomidou
Part of the Advances in Research on Neurodegeneration book series (ARN, volume 2)


Impairment of energy metabolism resulting in deterioration of the function of membranes, leading to loss of the Mg2+ block on N-methyl-D-aspartate (NMDA) receptors, allowing persistent activation of these receptors by endogenous glutamate is postulated as a mechanism to explain slow neuronal death in neurodegenerative disorders. Studies in rodents with mitochondrial respiratory chain toxins, aminoox-yacetic acid, 1-methyl-4-phenylpyridinium ion, and 3-nitropropionic acid, suggest that such mechanisms may indeed be involved in neurotoxicity produced by these agents. Nigral and striatal neurotoxicity induced by mitochondrial toxins in rodents reproduces neuropathology similar to that seen in humans suffering from Parkinson’s or Huntington’s disease, and can be prevented by NMDA receptor antagonists. Such observations indicate that glutamate may be involved in slow neuronal death leading to abiotrophic disorders and suggest the use of glutamate antagonists as potential neuroprotective agents to prevent or retard neuronal damage and death in relevant regions of the brain. Such an approach would consequently slow the rate of progression of these disabling disorders.


NMDA Receptor NMDA Antagonist Energy Failure Mitochondrial Energy Metabolism Excitotoxic Lesion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alston TA, Media L, Bright HJ (1977): 3-Nitropropionate, the toxic substance of Indigofera, is a suicide inactivator of succinate dehydrogenase. Proc Natl Acad Sci USA 74:3767–3771PubMedCrossRefGoogle Scholar
  2. Beal MF, Swartz KJ, Hyman BT, Storey E, Finn SF, Koroshetz W (1991): Aminooxyacetic acid results in excitotoxin lesions by a novel indirect mechanisms. J Neurochem 57:1068–1073PubMedCrossRefGoogle Scholar
  3. Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT (1993): Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13:4181–4192PubMedGoogle Scholar
  4. Brennan WA, Bird ED, Aprillo VR (1985): Regional mitochondrial metabolism in Huntington’s disease brain. J Neurochem 44:1448–1450CrossRefGoogle Scholar
  5. Brouillet E, Jenkins BG, Hyman BT, Ferrante RJ, Kowall NA, Srivastava R, Roy DS, Rosen BR, Beal MF (1993): Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J Neurochem 60:356–359PubMedCrossRefGoogle Scholar
  6. Brouillet EP, Shinobu L, McGarvey U, Beal MF (1993): Manganese injection into the rat striatum produces excitotoxic lesions by impairing energy metabolism. Exp Neurol 120:89–94PubMedCrossRefGoogle Scholar
  7. Choi DW (1992): Excitotoxic cell death. J Neurobiol 23:1261–1276PubMedCrossRefGoogle Scholar
  8. Corsini GU, Vaglini F, Fornai F, Saginario A, Zuddas A (1991): (+)MK 801 prevents dopaminergic perikarya damage in MPTP and acetaldehyde-treated mice. Posters Neurosci 1:33–36Google Scholar
  9. Di Monte D, Jewell SA, Ekstrom C, Sandy MS, Smith MT (1986): 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) cause rapid ATP depletion in isolated hepatocytes. Biochem Biophys Res Commun 137:310–315Google Scholar
  10. Gould DH, Gustine DL (1982): Basal ganglia degeneration, myelin alterations, and enzyme inhibition in mice by the plant toxin 3-nitropropanoic acid. Neuropathol Appl Neurobiol 8:377–393PubMedCrossRefGoogle Scholar
  11. Jenner P, Schapira AHV, Marsden CD (1992): New insights into the cause of Parkinson’s disease. Neurology 42:2241–2250PubMedCrossRefGoogle Scholar
  12. Lange KW, Youdim MBH, Riederer P (1992): Neurotoxicity and neuroprotection in Parkinson’s disease. J Neural Transm S38:27–44Google Scholar
  13. Ludolph A, He F, Spencer PS, Hammerstad J, Sabri M (1991): 3-Nitropropionic acid — exogenous animal neurotoxin and possible human striatal toxin. Can J Neurol Sci 18:492–498PubMedGoogle Scholar
  14. Miller RJ, Murphy SN, Glaum SR (1989): Neuronal Ca2+ channels and their regulation by excitatory amino acids. Ann NY Acad Sci 568:149–158PubMedCrossRefGoogle Scholar
  15. Mizuno Y, Suzuki K, Sone N, Saitoh T (1988): Inhibition of mitochondrial respiration by PTP in mouse brain in vivo. Neurosci Lett 91:349–353PubMedCrossRefGoogle Scholar
  16. Nicklas WJ, Vyas I, Heikkila RE (1985): Inhibition of NADH-linked oxidation in brain mitochondria by MPP+, a metabolite of the neurotoxin MPTP. Life Sci 36:2503–2508PubMedCrossRefGoogle Scholar
  17. Novelli A, Reilly JA, Lysko PG, Henneberry RC (1988): Glutamate becomes neurotoxic via the N-methyl-d-aspartate receptor when intracellular energy levels are reduced. Brain Res 451:205–212PubMedCrossRefGoogle Scholar
  18. Olney JW (1989): Excitatory amino acids and neuropsychiatric disorders. Biol Psychiatry 26:505–525PubMedCrossRefGoogle Scholar
  19. Orrenius S, Burkitt MJ, Kass GEN, Dypbukt JM, Nicotera P (1992): Calcium ions and oxidative cell injury. Ann Neurol 32:533–534CrossRefGoogle Scholar
  20. Parker WD, Boyson SJ, Luder AS, Parks JK (1990a): Evidence for a defect in NADH: ubiquinone oxidoreductase (complex I) in Huntington’s disease. Neurology 40: 1231–1234PubMedCrossRefGoogle Scholar
  21. Parker WD, Filley CM, Parks JG (1990b): Cytochrome oxidase deficiency in Alzheimer’s disease. Neurology 40:1302–1303PubMedCrossRefGoogle Scholar
  22. Rothman SM, Olney JW (1987): Excitotoxicity and the NMDA receptor. Trends Neurosci 10:299–302CrossRefGoogle Scholar
  23. Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD (1990): Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem 55:2142–2145PubMedCrossRefGoogle Scholar
  24. Schöls L, Reichmann H, Langkafel M, Kuhn W, Przuntek H (1992): Mitochondrial disorders in cerebellar ataxias. Mov Disord 7:S44Google Scholar
  25. Schwarcz R, Speciale C, Turski WA (1990): Kynurenines, glia and the pathogenesis of neurodegenerative disorders. In: Parkinsonism and Ageing, Calne DB, Comi G, Crippa D, Horowski R, Trabucchi M, eds., pp. 97–105. New York: Raven PressGoogle Scholar
  26. Stamler JS, Singel DJ, Loscalzo J (1992): Biochemistry of nitric oxide and its redoxactivated forms. Science 258: 1898–1902PubMedCrossRefGoogle Scholar
  27. Storey E, Hyman BT, Jenkins B, Brouillet E, Miller JM, Rosen BR, Beal MF (1992): 1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism. J Neurochem 58:1975–1978PubMedCrossRefGoogle Scholar
  28. Srivastava R, Brouillet E, Beal MF, Storey E, Hyman BT (1993): Blockade of 1-methyl-4-phenylpyridinium ion (MPP+) nigral toxicity in the rat by prior decortication or MK-801 treatment a stereological estimate of neuronal loss. Neurobial Aging 14:295–301CrossRefGoogle Scholar
  29. Turski L (1991): Excitatory amino acid antagonists and Parkinsons’s disease. In: Parkinson’s Disease — From Basic Research and Early Diagnosis to Long-Term Treatment, Rinne UK, Nagatsu T, Horowski R, eds., pp. 97–114. Bussum: MedicomGoogle Scholar
  30. Turski L, Melamed E (1993): Is there a role for excitatory amino acid antagonists? In: Parkinson’s Disease — Controversial Issues in therapy, Marsden CD, Oertel WH, eds., pp. 44–53. Bussum: MedicomGoogle Scholar
  31. Turski L, Bressler K, Rettig K-J, Löschmann P-A Wachtel H (1991): Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-d-aspartate antagonists. Nature 349:414–418PubMedCrossRefGoogle Scholar
  32. Turski WA (1991): Aminooxyacetic acid produces excitotoxic lesions in the rat substantia nigra. Naunyn-Schmiedebergs Arch Pharmacol 344:R67Google Scholar
  33. Turski WA, Urbañska E, Sieklucka M, Ikonomidou C (1992): Quinolinate-like neurotoxicity produced by aminooxyacetic acid in rat striatum. Amino Acids 2:245–253Google Scholar
  34. Urbańska E, Ikonomidou C, Sieklucka M, Turski WA (1989): Aminooxyacetic acid produces excitotoxic lesions in the rat striatum. Soc Neurosci Abstr 15:764Google Scholar
  35. Urbańska E, Ikonomidou C, Sieklucka M, Turski WA (1991): Aminooxyacetic acid produces excitotoxic lesions in the rat striatum. Synapse 9:129–135PubMedCrossRefGoogle Scholar
  36. Wallace DC (1992): Diseases of the mitochondrial DNA. Annu Rev Biochem 61:1175–1212PubMedCrossRefGoogle Scholar
  37. Youdim MBH (1993): The biology of toxic events in Parkinson’s disease. In: Advances in Research on Neurodegeneration, Vol. I, Calne DB, Horowski R, Mizuno Y, Poewe WH, Riederer P, Youdim MBH, eds., pp. 71–90. Boston: BirkhäuserGoogle Scholar
  38. Zeevalk GD, Nicklas WJ (1990): Chemically induced hypoglycemia and anoxia: relationship to glutamate receptor-mediated toxicity in retina. J Pharmacol Exp Ther 253:1285–1292PubMedGoogle Scholar
  39. Zeevalk GD, Nicklas WJ (1991): Mechanisms underlying initiation of excitotoxicity associated with metabolic inhibition. J Pharmacol Exp Ther 257: 870–878PubMedGoogle Scholar
  40. Zuddas A, Oberto G, Vaglini F, Fascëtti F, Fornai F, Corsini GU (1992): MK 801 prevents MPTP-induced parkinsonism in primates. J Neurochem 59:733–739PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Boston 1994

Authors and Affiliations

  • Lechoslaw Turski
  • Chrysanthy Ikonomidou

There are no affiliations available

Personalised recommendations